Component information
No US or EU label exists for this exact combination, so information is shown for each component.
- cinchocaine no separate page
Use: Adults and children 2 years of age and older: rinse half of a capful around in the mouth over affected area for at least 1 minute, then spit out. US FDA label
Note: Fixed-dose combinations may not allow the dose changes advised for each component; check the strength and use the single agents if a component needs adjusting.
Dosing: Altered kidney function
No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.
Kidney dosing for each component (single-agent) is shown under Component information.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosage forms
Philippines
- Suppository: 100 mg/2.5 mg
Registered products in the Philippines
1 product registered with the Food and Drug Administration (FDA) Philippines list Cinchocaine + Policresulen as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
FaktuPolicresulen + Cinchocaine hydrochloride | 100 mg/2.5 mg SuppositoryBox of 10 suppositories | Rx | Takeda (Werk Singen)Germany | Zuellig Pharma CorporationImporter: Takeda Healthcare Philippines Inc. | DR-XY092 | Oct 6, 2029 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .